Page 15 - Curis Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Curis inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Curis Inc Today - Breaking & Trending Today

Why Curis (CRIS) Shares Are Nosediving Thursday - Curis (NASDAQ:CRIS)

Curis, Inc. (NASDAQ: CRIS) shares are trading lower by 8.29% to $0.75 Thursday morning after the company announced a $15.1 million registered direct offering. ....

Curis Inc ,

Curis (CRIS) Prices 18.4M Share Offering at $0.82/sh

Curis (CRIS) Prices 18.4M Share Offering at $0.82/sh
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , New York , Curis Inc , Prospectus Department , Cantor Fitzgerald Co , Truist Securities Inc , Exchange Commission , Truist Securities , United States Securities , Post Effective Amendment , Cantor Fitzgerald , Capital Markets ,

U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BID

Curis, Inc. announced that the U.S. Food and Drug Administration has removed the partial clinical hold on the TakeAim Leukemia Phase 1/2 study of emavusertib. Further, the recommended phase 2 dose . ....

Curis Inc , Drug Administration , Takeaim Leukemia Phase , Acute Myelogenous Leukemia , Myelodysplastic Syndromes , Takeaim Leukemia , Complete Response , Partial Hematologic Recovery ,

Curis (CRIS) Announces FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID

Curis (CRIS) Announces FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

James Dentzer , Clinical Development Of Curis , Curis Inc , Drug Administration , Takeaim Leukemia Phase , Acute Myelogenous Leukemia , Myelodysplastic Syndromes , Takeaim Leukemia , Chief Executive Officer , Complete Response , Partial Hematologic Recovery , Senior Vice President , Clinical Development ,